Advances in Drug Therapy for HER2-positive Advanced Breast Carcinoma
Abstract
About 20% of breast cancer patients have HER2 gene overexpression, which usually shows strong invasion and high recurrence risk. Although HER2 targeted therapy has significantly improved patient prognosis, drug resistance remains a significant challenge in clinical treatment. In recent years, with the continuous development of targeted drugs, the application of new drugs has brought new hope for the treatment
of HER2 positive advanced breast cancer patients. This paper will focus on the current progress of drug therapy for HER2 positive advanced
breast cancer, and analyze the mechanism, clinical efficacy and potential in the treatment of new drugs.
Keywords
Full Text:
PDFReferences
[1] Gong Wenjing, Shi Xiuqing, Sun Ping. Research progress of HER2 positive and low expression antibody drug conjugates for advanced
breast cancer [J]. Chinese Journal of Cancer Clinical Sciences, 2025, 52 (02): 97-101.
[2] Jiang Mingxia, Li Qiao, Xu Binghe. Drug classification and clinical research progress of targeted therapy for HER2 positive advanced
breast cancer [J]. Chinese Journal of Cancer, 2024, 33 (07): 583-595.
[3] SwainSM, MilesD, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive-metastatic breast cancer (CLEOPATRA):
end of study results from a double-blind, randomised, placebo-controlled, phase study[J]. Lancet Oncol, 2020, 21(4):519-530.
[4] Zheng Xuan. Treatment status of HER2 positive advanced breast cancer and analysis of treatment strategy after trastuzumab resistance
[D]. Hebei Medical University, 2024.
[5] Chen Fei. Comparison of efficacy and safety of different second-line treatment schemes for trastuzumab resistant human epidermal
growth factor receptor 2 positive breast cancer [D]. Jilin University, 2021.
DOI: http://dx.doi.org/10.70711/mhr.v2i7.7446
Refbacks
- There are currently no refbacks.
